- Asia
- Automobile
- Bangladesh
- Banking
- Biological Inventions
- bLAWgathon
- Brand Valuation
- Business
- Celebrity Rights
- Company Act
- Company Law
- Competition Law
- Constitutional Law
- Consumer Law
- Copyright
- Copyright Infringement
- Copyright Litigation
- Corporate Law
- Counterfeiting
- Covid
- Design
- Digital Media
- Digital Right Management
- Educational Conferences/ Seminar
- EX-Parte
- Farmer Right
- Fashion Law
- FERs
- Foreign Law
- Gaming Industry
- GDPR
- GIg Economy
- Hi Tech Patent Commercialisation
- Hi Tech Patent Litigation
- IBC
- India
- Indonesia
- Intellectual Property
- Intellectual Property Protection
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- IVF technique
- Khadi Industries
- labour Law
- Legal Issues
- Licensing
- Live-in relationships
- Lok Sabha Bill
- Marriage Act
- Media & Entertainment Law
- Member of Parliament
- Myanmar
- NCLT
- NEPAL
- News & Updates
- Non-Disclosure Agreement
- Online Gaming
- Patent Act
- Patent Commercialisation
- Patent Fess
- Patent Filing
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Marketing
- Patent Opposition
- Patent Rule Amendment
- Patents
- pharma
- Pharma- biotech- Patent Commercialisation
- Pharma/Biotech Patent Litigations
- Pollution
- Protection of SMEs
- RERA
- Section 3(D)
- Signapore
- Social Media
- Sports Law
- Stamp Duty
- Stock Exchange
- Surrogacy in India
- TAX
- Technology
- Telecom Law
- Telecommunications
- Thailand
- Trademark
- Trademark Infringement
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
CIPLA & BMS may settle patent dispute over Entecavir in India
30th May, 2015 - 12:16 pm
Categories:
IPAB
IPAB Decisions
News & Updates
patent infringement
Patents
pharma
0 Comments
US based pharma major Bristol-Myers Squibb (BMS) and Indian pharma company Cipla Ltd. are heading towards an amicable settlement on a long-stretched patent dispute concerning BMS’ hepatitis B drug Entecavir, a leading anti-viral drug for Hepatitis B patients that brings in more than a billion dollars each year globally for BMS. Entecavir, being a pre-1995 … Continue reading CIPLA & BMS may settle patent dispute over Entecavir in India
Read more »Part 3 of 3: Patent Term Extension laws for Europe and the United States of America: compared and contrasted
This is third and last part of the three part series dedicated to the discussion on the comparison of the Patent Term Extension laws of Europe and the United States of America (USA). While part one of three, which discussed the comparison of terms used for the extension of patent term in Europe and the … Continue reading Part 3 of 3: Patent Term Extension laws for Europe and the United States of America: compared and contrasted
Read more »Part 2 of 3: Patent Term Extension laws for Europe and the United States of America: compared and contrasted
This is second part of the three part series dedicated to the discussion on the comparison of the Patent Term Extension laws of Europe and the United States of America (USA). While part one of three, which discussed the comparison of terms used for the extension of patent term in Europe and the USA, relevant … Continue reading Part 2 of 3: Patent Term Extension laws for Europe and the United States of America: compared and contrasted
Read more »Part 1 of 3: Patent Term Extension laws for Europe and the United States of America: compared and contrasted
Many people love comparing and contrasting and I am one of those (at least for study purposes). This time, I am comparing Patent Term Extension laws for Europe and the United States of America (USA). Though there are other provisions that may extend the life of patent such as patent term adjustment to compensate the … Continue reading Part 1 of 3: Patent Term Extension laws for Europe and the United States of America: compared and contrasted
Read more »